Physician profile
Robert Ring
NPI 1336228840
$4,814.41
in general payments reported to CMS, 2019-2025
10 companies · $85.16 in 2025
The $85.16 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $36.64 · 2021: $17.59 · 2023: $4,460 · 2024: $215 · 2025: $85.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,338 · Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,337.82 |
| Food and Beverage | $422.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $4,337.82 | 2023 | |
| Apellis Pharmaceuticals, INC. | $121.87 | 2023 | |
| Coopervision INC. | $120.46 | 2021-2024 | Ortho-K Contact Lens |
| Bausch & Lomb Americas INC. | $58.58 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $51.68 | 2024 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $34.70 | 2025 | Eylea Hd |
| Harrow Eye, LLC | $30.77 | 2025 | Triesence |
| Abbvie INC. | $21.89 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.